Maya Katz, MD

Neurologist

Dr. Maya Katz is a neurologist at the UCSF Movement Disorder and Neuromodulation Center. She specializes in treating patients with Parkinson's disease, essential tremor, dystonia and other movement disorders. Her research interests include identifying ways to delay Parkinson's disease progression and improving outcomes for patients treated with deep brain stimulation. She is also interested in multidisciplinary approaches to the treatment of advanced movement disorders.

Katz earned her bachelor's degree and her medical degree from Cornell University. She completed her internship and residency at Mount Sinai Hospital and her neurology fellowship in movement disorders at UCSF.

Clinics

Movement Disorder and Neuromodulation Center
1635 Divisadero St., Suite 520
San Francisco, CA 94115
Neurology: (415) 353-2311
Neurosurgery: (415) 353-2071
Fax: (415) 353-9060

Hours: Monday to Friday
8 a.m. – 5 p.m.

Conditions & Treatments

Board Certification

Neurology, American Board of Psychiatry and Neurology

Academic Title

Assistant Professor

More about Maya Katz

Education

Weill Cornell Medical College 2007

Residencies

Mount Sinai Medical Center, Neurology 2011

Fellowships

UCSF Medical Center, Movement Disorders 2013

Selected Research and Publications

  1. Beck CA, Beran DB, Biglan KM, Boyd CM, Dorsey ER, Schmidt PN, Simone R, Willis AW, Galifianakis NB, Katz M, Tanner CM, Dodenhoff K, Aldred J, Carter J, Fraser A, Jimenez-Shahed J, Hunter C, Spindler M, Reichwein S, Mari Z, Dunlop B, Morgan JC, McLane D, Hickey P, Gauger L, Richard IH, Mejia NI, Bwala G, Nance M, Shih LC, Singer C, Vargas-Parra S, Zadikoff C, Okon N, Feigin A, Ayan J, Vaughan C, Pahwa R, Dhall R, Hassan A, DeMello S, Riggare SS, Wicks P, Achey MA, Elson MJ, Goldenthal S, Keenan HT, Korn R, Schwarz H, Sharma S, Stevenson EA, Zhu W. National randomized controlled trial of virtual house calls for Parkinson disease. Neurology. 2017 Sep 12; 89(11):1152-1161.
  2. Korn RE, Wagle Shukla A, Katz M, Keenan HT, Goldenthal S, Auinger P, Zhu W, Dodge M, Rizer K, Achey MA, Byrd E, Barbano R, Richard I, Andrzejewski KL, Schwarz HB, Dorsey ER, Biglan KM, Kang G, Kanchana S, Rodriguez R, Tanner CM, Galifianakis NB. Virtual visits for Parkinson disease: A multicenter noncontrolled cohort. Neurol Clin Pract. 2017 08; 7(4):283-295.
  3. LaHue SC, Ostrem JL, Galifianakis NB, San Luciano M, Ziman N, Wang S, Racine CA, Starr PA, Larson PS, Katz M. Parkinson's disease patient preference and experience with various methods of DBS lead placement. Parkinsonism Relat Disord. 2017 Aug; 41:25-30.
  4. Kluger BM, Fox S, Timmons S, Katz M, Galifianakis NB, Subramanian I, Carter JH, Johnson MJ, Richfield EW, Bekelman D, Kutner JS, Miyasaki J. Palliative care and Parkinson's disease: Meeting summary and recommendations for clinical research. Parkinsonism Relat Disord. 2017 Apr; 37:19-26.
  5. Dorsey ER, Achey MA, Beck CA, Beran DB, Biglan KM, Boyd CM, Schmidt PN, Simone R, Willis AW, Galifianakis NB, Katz M, Tanner CM, Dodenhoff K, Ziman N, Aldred J, Carter J, Jimenez-Shahed J, Hunter C, Spindler M, Mari Z, Morgan JC, McLane D, Hickey P, Gauger L, Richard IH, Bull MT, Mejia NI, Bwala G, Nance M, Shih L, Anderson L, Singer C, Zadikoff C, Okon N, Feigin A, Ayan J, Vaughan C, Pahwa R, Cooper J, Webb S, Dhall R, Hassan A, Weis D, DeMello S, Riggare SS, Wicks P, Smith J, Keenan HT, Korn R, Schwarz H, Sharma S, Stevenson EA, Zhu W. National Randomized Controlled Trial of Virtual House Calls for People with Parkinson's Disease: Interest and Barriers. Telemed J E Health. 2016 07; 22(7):590-8.
  6. Reyes RC, Cittolin-Santos GF, Kim JE, Won SJ, Brennan-Minnella AM, Katz M, Glass GA, Swanson RA. Erratum to: Neuronal Glutathione Content and Antioxidant Capacity can be Normalized In Situ by N-acetyl Cysteine Concentrations Attained in Human Cerebrospinal Fluid. Neurotherapeutics. 2016 Jan; 13(1):239.
  7. Reyes RC, Cittolin-Santos GF, Kim JE, Won SJ, Brennan-Minnella AM, Katz M, Glass GA, Swanson RA. Neuronal Glutathione Content and Antioxidant Capacity can be Normalized In Situ by N-acetyl Cysteine Concentrations Attained in Human Cerebrospinal Fluid. Neurotherapeutics. 2016 Jan; 13(1):217-25.
  8. Ostrem JL, Ziman N, Galifianakis NB, Starr PA, Luciano MS, Katz M, Racine CA, Martin AJ, Markun LC, Larson PS. Clinical outcomes using ClearPoint interventional MRI for deep brain stimulation lead placement in Parkinson's disease. J Neurosurg. 2016 Apr; 124(4):908-16.
  9. Katz M, Luciano MS, Carlson K, Luo P, Marks WJ, Larson PS, Starr PA, Follett KA, Weaver FM, Stern MB, Reda DJ, Ostrem JL. Differential effects of deep brain stimulation target on motor subtypes in Parkinson's disease. Ann Neurol. 2015 Apr; 77(4):710-9.
  10. Katz M, Won SJ, Park Y, Orr A, Jones DP, Swanson RA, Glass GA. Cerebrospinal fluid concentrations of N-acetylcysteine after oral administration in Parkinson's disease. Parkinsonism Relat Disord. 2015 May; 21(5):500-3.
  11. Chan YF, Katz M, Moskowitz A, Levine SR, Richardson LD, Tuhrim S, Chason K, Barsan-Silverman K, Singhal A. Supplemental oxygen delivery to suspected stroke patients in pre hospital and emergency department settings. Med Gas Res. 2014; 4:16.
  12. Katz M, Byl NN, San Luciano M, Ostrem JL. Focal task-specific lower extremity dystonia associated with intense repetitive exercise: a case series. Parkinsonism Relat Disord. 2013 Nov; 19(11):1033-8.
  13. Cheung T, Nuņo M, Hoffman M, Katz M, Kilbane C, Alterman R, Tagliati M. Longitudinal impedance variability in patients with chronically implanted DBS devices. Brain Stimul. 2013 Sep; 6(5):746-51.
  14. Bryson EO, Aloysi AS, Katz M, Popeo D, Kellner CH. Rocuronium as muscle relaxant for electroconvulsive therapy in a patient with adult-onset muscular dystrophy. J ECT. 2011 Dec; 27(4):e63-4.
  15. Katz M, Kilbane C, Rosengard J, Alterman RL, Tagliati M. Referring patients for deep brain stimulation: an improving practice. Arch Neurol. 2011 Aug; 68(8):1027-32.
  16. Dumont M, Kipiani K, Yu F, Wille E, Katz M, Calingasan NY, Gouras GK, Lin MT, Beal MF. Coenzyme Q10 decreases amyloid pathology and improves behavior in a transgenic mouse model of Alzheimer's disease. J Alzheimers Dis. 2011; 27(1):211-23.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.